Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 13.09% | -17.01% | -4.97% | -7.13% | -2.04% |
| Total Depreciation and Amortization | 5.73% | 2.61% | 10.47% | 12.15% | 17.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.18% | 2.73% | 8.59% | 9.79% | -15.39% |
| Change in Net Operating Assets | -179.03% | 420.57% | 60.71% | -247.31% | 280.81% |
| Cash from Operations | -50.85% | 23.37% | 10.68% | -75.03% | 25.08% |
| Capital Expenditure | 25.13% | -24.52% | 67.23% | -74.86% | 1.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 25.13% | -24.52% | 67.23% | -74.86% | 1.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -51.60% | 4,240.21% | -97.71% | 126.57% | 22,189.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -100.00% | 74.90% | -286.57% | -148.15% |
| Cash from Financing | -51.56% | 4,316.43% | -97.75% | 126.42% | 24,285.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.61% | 441.88% | -132.87% | 157.31% | 226.30% |
